Josh Resnick, MD, MBA, is a venture capitalist with more than extensive experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. He has founded multiple companies in the neurodegeneration and immunology/IO space.
Currently, Dr. Resnick is a managing director at RA Capital Management where he leads early-stage private investments and oversees the creation of new companies developing drugs, medical devices, diagnostics, and research tools. He previously co-led SV Health Investors’ U.S. biotech practice where he was responsible for SV’s U.S. venture creation activities, including its incubator, Brahma Discovery. Before SV, Dr. Resnick was President and Managing Partner at Merck’s MRL Ventures Fund. Prior to MRL Ventures, Dr. Resnick was a venture partner with Atlas Venture and a partner at Prism Venture Partners, focusing on company formation as well as seed and Series A investing. Dr. Resnick is a faculty member at Harvard Medical School and an attending physician in the Department of Emergency Medicine at Brigham and Women’s Hospital.
Dr. Resnick holds a bachelor’s degree in chemistry from Williams College, a Doctor of Medicine from the University of Pennsylvania School of Medicine, and a Master of Business Administration from University of Pennsylvania’s Wharton School of Business.